Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-794
Abstract: Introduction: The FLAIR (ISRCTN01844152) phase III trial for previously untreated fit CLL patients showed that measurable residual disease (MRD)-guided ibrutinib-venetoclax (I+V) significantly improved response, progression-free survival (PFS), and overall survival (OS) compared to ibrutinib-alone (IBR)… read more here.
Keywords: treatment; mrd eot; mrd relapse; cll ... See more keywords